Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Bradley on Radiation Therapy in Lung Cancer

July 29th 2013

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses ongoing research involving radiation therapy for lung cancer.

Second-Generation ALK Inhibitors Show Promise in Early-Stage NSCLC Trials

July 29th 2013

Although crizotinib (Xalkori) is highly effective in treating patients with advanced ALK-positive non–small cell lung cancer (NSCLC), most patients develop resistance to the drug.

Dr. Lynch Accepts His 'Giants of Cancer Care' Award

July 29th 2013

Thomas J. Lynch, Jr., MD, from the Yale Cancer Center, pioneered the use of molecular testing for EGFR mutations in lung cancer. In July 2013, he was honored by OncLive as one of the "Giants of Cancer Care."

Dr. Gandara Spotlights the Giants of Cancer Care

July 26th 2013

David R. Gandara, MD, from the UC Davis Cancer Center, discusses the 2013 recipient of the Giants in Cancer Care award in the field of thoracic oncology: Thomas J. Lynch, Jr., MD.

Dr. Carbone on Genetic Testing Availability and Accuracy

July 25th 2013

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, describes variations in the accuracy and availability of genetic testing technologies.

Dr. Shaw Compares Crizotinib and Chemotherapy in NSCLC

July 19th 2013

Lead author, Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital, reviews the first published results from a randomized phase III trial investigating crizotinib in patients with ALK-positive non-small cell lung cancer.

Dr. Ramalingam on Hsp90 Inhibition With Ganetespib

July 18th 2013

Suresh S. Ramalingam, MD, from the Winship Cancer Institute of Emory University, discusses the role of heat shock proteins in normal cells and their potential role in treating cancer.

Matthew Lara on Younger Vs Older Patients With NSCLC

July 17th 2013

Primo Lara, MD, and his son, Matthew Stephen Lara, discuss an analysis of predictors of survival for younger patients with non-small cell lung cancer.

FDA Approves Afatinib for Metastatic NSCLC

July 12th 2013

The FDA has approved afatinib, along with a companion diagnostic, to treat patients with metastatic non-small cell lung cancer who express specific types of EGFR mutations.

Dr. Gandara on the Heat Shock Protein 90 Inhibitor Ganetespib

July 1st 2013

David R. Gandara, MD, from UC Davis Cancer Center, discusses treatment with the heat shock protein 90 inhibitor ganetespib.

Potential Biomarkers Identified for Predicting Response to Drugs Targeting KRAS-Mutated NSCLC

July 1st 2013

Investigators identified three proteins that were able to predict response to treatment with a MEK inhibitor plus a PI3 kinase inhibitor-an investigational approach to NSCLC, including some KRAS-mutated cancers.

Dr. Bradley on the Background of the RTOG 0617 Study

June 18th 2013

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses the background of the phase III RTOG 0617 study.

New Guidelines, Therapies in Spotlight at PER Congress

June 18th 2013

Discussions about new guidelines on molecular testing in patients with lung cancer and a keynote address from prominent researcher Tony S. Mok, MD, will be among the highlights of the upcoming 14th International Lung Cancer Congress.

Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer

June 14th 2013

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

Dr. Camidge on Crizotinib as a ROS1 Inhibitor in NSCLC

June 13th 2013

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the use of crizotinib as a ROS1 inhibitor in non-small cell lung cancer (NSCLC).

Study Suggests Role for Targeting HER2 in Non-Small Cell Lung Cancer

June 13th 2013

Mutations of the HER2 gene in patients with non-small cell lung cancer, though rare, potentially could be treated with HER2-targeted drugs.

Novel Hsp Inhibitor May Offer NSCLC Salvage Option

June 7th 2013

Salvage therapy combining the novel heat shock protein 90 inhibitor ganetespib with docetaxel significantly improved overall survival in some patients with non–small cell lung cancer.

Dr. Shaw Describes LDK378 in ALK-Positive Lung Cancer

June 5th 2013

Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital Cancer Center, discusses the clinical activity of the ALK inhibitor LDK378 in patients with non-small cell lung cancer harboring an ALK alteration.

Dr. Herbst on the Emergence of Immunotherapy in Cancer

June 5th 2013

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, describes the emergence of immunotherapy as a treatment in multiple types of cancer that was highlighted at the 2013 ASCO Annual Meeting.

Dr. Ramalingam Reviews the GALAXY-1 Trial Results

June 3rd 2013

Suresh S. Ramalingam, MD, from the Winship Cancer Institute, describes results from the phase II GALAXY-1 trial that explored the Hsp90 inhibitor ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma.

NEXT PAGE
PREVIOUS PAGE